Published in Front Oncol on June 24, 2014
The Mitogen-Activated Protein Kinase (MAPK) Pathway: Role in Immune Evasion by Trypanosomatids. Front Microbiol (2016) 0.80
A novel somatic mutation in ACD induces telomere lengthening and apoptosis resistance in leukemia cells. BMC Cancer (2015) 0.80
Drugging the unfolded protein response in acute leukemias. J Hematol Oncol (2015) 0.79
Gene network analysis shows immune-signaling and ERK1/2 as novel genetic markers for multiple addiction phenotypes: alcohol, smoking and opioid addiction. BMC Syst Biol (2015) 0.78
Perspectives of the Nrf-2 signaling pathway in cancer progression and therapy. Toxicol Rep (2017) 0.77
Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia. PLoS One (2015) 0.76
Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes. Oncotarget (2016) 0.76
MEK1 is required for the development of NRAS-driven leukemia. Oncotarget (2016) 0.75
Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol Lett (2017) 0.75
Somatic MAP2K1 Mutations Are Associated with Extracranial Arteriovenous Malformation. Am J Hum Genet (2017) 0.75
Mutational analysis of the RAS/RAF/MEK/ERK signaling pathway in 260 Han Chinese patients with cervical carcinoma. Oncol Lett (2017) 0.75
Carboxyl terminus-truncated α1D-adrenoceptors inhibit the ERK pathway. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
w09, a novel autophagy enhancer, induces autophagy-dependent cell apoptosis via activation of the EGFR-mediated RAS-RAF1-MAP2K-MAPK1/3 pathway. Autophagy (2017) 0.75
B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy. Oncotarget (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer (2007) 10.27
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25
Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature (2010) 8.48
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer (2011) 6.45
Senescence in tumours: evidence from mice and humans. Nat Rev Cancer (2010) 6.34
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res (2007) 5.59
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood (2001) 5.17
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature (2013) 4.43
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol (2009) 4.20
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci (2011) 3.89
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75
CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell (2012) 3.39
GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res (2011) 3.36
BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell (1993) 2.92
Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol (2011) 2.81
Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ (2008) 2.44
Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood (2004) 2.42
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood (2004) 2.19
RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes Cancer (2011) 2.12
K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors. Blood (2008) 2.10
FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program (2006) 2.02
Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia. Leukemia (2005) 1.95
K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood (2006) 1.93
FLT3 mutations in childhood acute lymphoblastic leukemia. Blood (2003) 1.91
Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res (2008) 1.77
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol (2010) 1.73
Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. Blood (2007) 1.72
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature (2009) 1.72
Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner. Blood (2011) 1.70
AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood (2005) 1.69
Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol (2009) 1.67
Targeting oncogenic Ras signaling in hematologic malignancies. Blood (2012) 1.67
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs (2010) 1.62
Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness. Nature (2013) 1.61
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol (2008) 1.57
Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene (2002) 1.56
Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia. Leuk Res (1999) 1.54
Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood (2008) 1.51
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia (2011) 1.51
Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer (2008) 1.39
K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. Cancer (2006) 1.39
RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia (2004) 1.38
The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood (2009) 1.37
Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells. J Exp Med (2011) 1.37
A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood (2006) 1.35
Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol (2004) 1.30
FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood (2004) 1.30
FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood (2003) 1.26
Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci U S A (2010) 1.25
Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. Blood (2003) 1.25
Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Res (1996) 1.21
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood (2005) 1.20
Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations. Leukemia (2010) 1.19
RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia. Leukemia (2005) 1.17
Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro. J Biol Chem (2003) 1.12
Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants. Haematologica (2013) 1.11
Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood (1993) 1.09
Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development. Immunol Res (2011) 1.09
The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood (1990) 1.08
N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. Blood (1990) 1.07
Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2010) 1.05
MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM. Leukemia (2009) 1.05
PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia. Leuk Res (2006) 1.05
Activation of the RAS pathway is predictive for a chemosensitive phenotype of acute myelogenous leukemia blasts. Clin Cancer Res (2005) 1.04
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Br J Cancer (2012) 1.03
Mutational analysis of the N-ras gene in acute lymphoblastic leukemia: a study of 125 Japanese pediatric cases. Int J Hematol (1998) 1.02
BRAF mutations are very rare in B- and T-cell pediatric acute lymphoblastic leukemias. Leukemia (2008) 1.02
Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy. PLoS One (2009) 1.01
Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia. Blood (2013) 1.00
FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia. BMC Cancer (2010) 0.99
Parental exposure to medications and hydrocarbons and ras mutations in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Cancer Epidemiol Biomarkers Prev (2004) 0.99
ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation in human acute leukemias. Proc Natl Acad Sci U S A (2007) 0.97
Activated K-Ras protein accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model. Leukemia (2011) 0.97
Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation. J Biol Chem (2013) 0.97
Converting cell lines representing hematological malignancies from glucocorticoid-resistant to glucocorticoid-sensitive: signaling pathway interactions. Leuk Res (2008) 0.96
Backtracking RAS mutations in high hyperdiploid childhood acute lymphoblastic leukemia. Blood Cells Mol Dis (2010) 0.95
Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo. Blood (2013) 0.95
Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia. Med Oncol (2008) 0.92
Distinct requirements of hematopoietic stem cell activity and Nras G12D signaling in different cell types during leukemogenesis. Cell Cycle (2011) 0.90
Ras oncogene-induced sensitization to 1-beta-D-arabinofuranosylcytosine. Cancer Res (1999) 0.89
Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer (2011) 0.87
PTPN11 mutations in childhood acute lymphoblastic leukemia occur as a secondary event associated with high hyperdiploidy. Leukemia (2009) 0.86
Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia. Leuk Res (2012) 0.85
Mechanisms of aneuploidy induction by RAS and RAF oncogenes. Am J Cancer Res (2011) 0.84
In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. Blood (2005) 0.81
Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11). J Med Chem (2013) 0.81
FLT3 mutations in a 10 year consecutive series of 177 childhood acute leukemias and their impact on global gene expression patterns. Genes Chromosomes Cancer (2008) 0.81